MBX Biosciences (NASDAQ:MBX) Stock Rating Lowered by Wall Street Zen

Key Points

• MBX Biosciences has been downgraded from a "hold" rating to a "sell" rating by analysts at Wall Street Zen.
• The company's stock opened at $11.55, with a market cap of $387.96 million and a P/E ratio of -2.54.
• MBX Biosciences specializes in developing novel precision peptide therapies for endocrine and metabolic disorders.

MBX Biosciences (NASDAQ:MBX - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Friday.

MBX Biosciences Price Performance

Shares of NASDAQ MBX opened at $11.55 on Friday. The company has a market cap of $387.96 million and a P/E ratio of -2.54. MBX Biosciences has a 12-month low of $4.81 and a 12-month high of $27.50.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.